本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司全资子公司江西鑫威康贸易有限公司（以下简 称"鑫威康"）因经营需要，对《医疗器械经营许可证》《食品经营许可证》所登 载的法定代表人进行了变更并完成了变更登记手续，鑫威康于近日取得了由南昌市 市场监督管理局颁发的《医疗器械经营许可证》以及南昌县市场监督管理局颁发的 《食品经营许可证》，现将具体内容公告如下： 一、变更情况 | 《医疗器械经营许可证》 | | | | --- | --- | --- | | 变更事项 | 变更前内容 | 变更后内容 | | 法定代表人 | 毛志平 | 万红艳 | 证券代码：300453 证券简称：三鑫医疗 公告编号：2023-057 江西三鑫医疗科技股份有限公司 关于全资子公司完成医疗器械经营许可证 及食品经营许可证变更登记的公告 企业负责人：万红艳 住所：江西省南昌市南昌县小蓝经济技术开发区富山大道 999 号 | 《食品经营许可证》 | | | | --- | --- | --- | | 变更事项 | 变更前内容 | 变更后内容 | | 法定代表人（负责人） ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2023-056 江西三鑫医疗科技股份有限公司 关于参股公司完成工商变更登记的公告 名称：厦门精配软件工程有限公司 统一社会信用代码：91350200302842924Q 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日披露了《关于参股公司增资暨公司放弃优先认缴出资权的公告》（公告编号： 2023-053），参股公司厦门精配软件工程有限公司（以下简称"厦门精配软件"） 因业务拓展需要，拟进行增资。公司基于发展战略考量，放弃本次厦门精配软件 增资扩股的优先认缴出资权。厦门精配软件由上海健麾信息技术股份有限公司出 资 2,250 万元进行增资，其中 284.3243 万元计入注册资本，剩余 1,965.6757 万元计入资本公积。本次增资完成后，厦门精配软件注册资本将由 1,611.1708 万元增加至 1,895.4951 万元，公司持有厦门精配软件的股权比例将由 24.00%下 降至 20.40%。 一、营业执照基本登记信息 成立日 ...

江西三鑫医疗科技股份有限公司 证券代码：300453 证券简称：三鑫医疗 公告编号：2023-055 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司全资子公司江西鑫威康贸易有限公司因经营需 要对法定代表人进行了变更，并于近日取得了由南昌县市场监督管理局换发的《营 业执照》。工商变更情况如下： 一、工商信息变更情况 | 变更事项 | 变更前内容 | 变更后内容 | | --- | --- | --- | | 法定代表人 | 毛志平 | 万红艳 | 二、营业执照基本登记信息 名称：江西鑫威康贸易有限公司 统一社会信用代码：91360121MA382JHM05 类型：有限责任公司（自然人投资或控股的法人独资） 法定代表人：万红艳 关于全资子公司变更法定代表人完成工商变更登记的公告 销售，消毒剂销售（不含危险化学品），化妆品批发，化妆品零售，日用品销售， 日用百货销售，劳动保护用品销售，体育用品及器材零售，电子产品销售，软件销 售，互联网销售（除销售需要许可的商品），普通货物仓储服务（不含危险化学品 等需许可审批的项目），医疗设备租赁，专用设备 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2023-053 根据《深圳证券交易所创业板股票上市规则》《公司章程》及《董事会议事规 则》等相关规定，本次公司就厦门精配软件增资事项放弃优先认缴出资权无需提交 董事会和股东大会审议。 本次增资事项不构成关联交易，也不构成重大资产重组。 二、交易对方的基本情况 企业名称：上海健麾信息技术股份有限公司 统一社会信用代码：913101203986677289 企业类型：股份有限公司(上市、自然人投资或控股) 法定代表人：戴建伟 注册资本：人民币 13600.0000 万元整 江西三鑫医疗科技股份有限公司 关于参股公司增资暨公司放弃优先认缴出资权的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、基本情况概述 江西三鑫医疗科技股份有限公司（以下简称"公司"或"三鑫医疗"）参股公 司厦门精配软件工程有限公司（以下简称"厦门精配软件"）因业务拓展需要，拟 进行增资。基于公司发展战略考量，公司放弃本次厦门精配软件增资扩股的优先认 缴出资权。厦门精配软件由上海健麾信息技术股份有限公司（以下简称"健麾信息"） 出资 2, ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2023-052 江西三鑫医疗科技股份有限公司 一、基本情况概述 关于与专业投资机构共同投资合伙企业的进展公告 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2023 年 7 月 6 日签署 了《矩阵纵横三号（海南）股权投资基金合伙企业（有限合伙）之合伙协议》，公 司作为有限合伙人以自有资金出资 1000 万元，与矩阵（海南）私募基金管理有限公 司、北京中亿百祥信息咨询中心（有限合伙）、北京中财开银信息咨询中心（有限 合伙）共同投资矩阵纵横三号（海南）股权投资基金合伙企业（有限合伙）（以下 简称"矩阵纵横三号"）。矩阵纵横三号已于 2023 年 7 月 24 日完成了相关工商变 更登记手续。具体内容详见公司分别于 2023 年 7 月 10 日、2023 年 7 月 28 日在巨 潮资讯网披露的《关于与专业投资机构共同投资合伙企业的公告》（公告编号： 2023-040）、《关于与专业投资机构共同投资合伙企业的进展公告》（公告编号： 2023-044）。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 二、基 ...

证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 编号：20230811 | --- | --- | --- | |----------------|--------------|--------------------------------------| | | 特定对象调研 | 分析师会议 | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 | 路演活动 | | 类别 | 现场参观 | 其他 2023 年半年度业绩交流会（电话会 | 议） 东吴证券 华安证券 国元证券 申万菱信 聚鸣投资 永赢基金 参与单位名称 安信证券 华宝基金 汇丰晋信 浦银安盛 鹏华基金 万家基金 信达澳亚 时间 2023年8月10日-2023年8月11日 地点 电话会议 上市公司接待 董事、副总裁、董事会秘书 刘明 人员姓名 证券事务代表 周文燕 一、简要介绍公司主营业务等基本情况 公司董事、副总裁、董事会秘书刘明简要介绍了公司 2023 年上半 年经营情况。 2023 年上半年，公司实现营业收入 58,174.55 万元，较上年同期下 降 11.88% ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2023-051 江西三鑫医疗科技股份有限公司 关于获得血液透析浓缩液注册证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）于近日取得了国家药品 监督管理局颁发的《医疗器械注册证》，现将主要情况公告如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 注册 分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | | | | 2023年8月9日 | | 适用于急、慢性肾 | | 1 | 血液透析浓 | 国械注准 | 至 | Ⅲ类 | 功能衰竭患者的血 | | | 缩液 | 20233101134 | 2028年8月8日 | | 液透析治疗。 | 一、医疗器械注册证的主要内容 二、对公司的影响 公司本次获得医疗器械注册证的血液透析浓缩液由 A 液和 B 液组成。A 液由氯 化钠、氯化钾、氯化钙、氯化镁和冰醋酸组成，B 液由碳酸氢钠组成。 低钙血症是慢性肾衰竭患者特别是透析患者最常见的并发症之一。本次 ...

证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 编号：20230809 | --- | --- | --- | |----------------|--------------|--------------------------------------| | | 特定对象调研 | 分析师会议 | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 | 路演活动 | | 类别 | 现场参观 | 其他 2023 年半年度业绩交流会（电话会 | 议） 华创证券 西南证券 东吴证券 华安证券 国盛证券 国信证券 国元证券 兴业基金 光大证券 国联证券 国金资管 天弘基金 中意资产 AZIMUT（安中） 淡水泉投资 万和弘远 金之灏 金元顺安 泰康资产 易米基金 敦和资管 野村资管 正圆投资 明河投资 源峰基金 湘财基金 阿尔法 沣谊投资 明世伙伴 格林基金 信达澳亚 泰信基金 富安达 和谐汇一 环懿基金 鹤禧投资 优益增 安信资管 中天国富 生命保险 东证衍生品 国华兴益 参与单位名称 南方基金 世纪证券 建信基金 汇添富 恒立基金 建信养老 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, achieving a total of RMB 500 million, representing a growth of 15% compared to the same period in 2022[23]. - The company's operating revenue for the reporting period was ¥581,745,548.36, a decrease of 11.88% compared to ¥660,203,926.41 in the same period last year[29]. - The net profit attributable to shareholders was ¥89,479,881.40, down 14.57% from ¥104,736,931.56 year-on-year[29]. - The net profit after deducting non-recurring gains and losses was ¥78,449,998.15, reflecting a decline of 20.35% compared to ¥98,496,899.72 in the previous year[29]. - The net cash flow from operating activities increased by 12.48% to ¥98,210,338.19 from ¥87,312,813.69 in the same period last year[29]. - The company will not distribute cash dividends or issue bonus shares for the current fiscal year, opting to reinvest profits into growth initiatives[11]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting a 25% increase in market share within the domestic medical device sector by the end of 2024[9]. - The company has set a revenue guidance for the second half of 2023, projecting an increase of 10% to 15% over the first half figures[5]. - The company is focusing on enhancing its core competitive advantages through continuous product development and improving service quality[46]. - The company aims to become a leading manufacturer in the blood purification industry and is expanding into early and mid-stage kidney disease interventions[46]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a budget of RMB 100 million earmarked for this purpose[9]. Product Development and Innovation - New product development includes the launch of a next-generation blood purification device, expected to enhance treatment efficiency by 30%[10]. - The company has allocated RMB 50 million for research and development in new technologies, focusing on innovative medical devices[10]. - The company has launched new products including a disposable dialysis catheter, which is the first domestically produced variety in its category, enhancing its competitive edge[38]. - The company has developed a complete product chain for blood dialysis, including key technologies that are internationally advanced[49]. - The company has developed new products focusing on safety performance, including needle-free injectors and precision-filtering infusion devices, enhancing safety and user experience in clinical settings[67]. Research and Development - The company has over 30 ongoing research projects, with more than 10 projects specifically focused on vascular intervention products[38]. - The company reported a research and development investment of 33.34 million yuan, accounting for 5.73% of the revenue during the reporting period, with a year-on-year growth of 12.84%[114]. - As of the end of the reporting period, the company had 122 authorized patents and 71 pending patents, with 91 medical device product registration certificates held[114]. - The company has established several research platforms to drive innovation in medical devices[57]. - The company has established a collaborative R&D model with universities and research institutions to drive innovation in blood purification and other medical technologies[103]. Competitive Landscape - The competitive landscape in the blood purification market remains challenging, with foreign companies holding a significant market share, necessitating strategic pricing adjustments[9]. - The blood dialysis machine market in China is dominated by imports, accounting for 80%-90% of the market share, while domestic brands hold only 10%-20%[56]. - The domestic blood purification market is highly competitive, with significant pressure on pricing due to centralized procurement policies[146]. - The company is addressing the impact of medical device procurement policies on product pricing and market competition[149]. Social Responsibility and Community Engagement - The company has been recognized as a "Leading Enterprise in Social Responsibility" by the Jiangxi Provincial Federation of Industry and Commerce in 2022[165]. - The company donated 1 million yuan to the Nanchang University First Affiliated Hospital for kidney transplant assistance, aimed at alleviating the financial burden on economically disadvantaged kidney disease patients[166]. - The company organized the "2023 Sanxin Medical Kidney Friends Exchange Conference" to enhance communication among kidney disease patients, healthcare professionals, and the company, focusing on improving product quality and patient care[166]. - The company emphasized its commitment to social responsibility and public welfare, aiming to contribute to a healthier and happier society[166]. Regulatory and Compliance - The company has been recognized as a "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration[121]. - The company has participated in the formulation and revision of 2 national standards and 4 industry standards related to infusion products, enhancing its industry position and market competitiveness[69]. - The company has established a comprehensive environmental management system to enhance pollution control and ensure compliance with emission standards[161]. - The company has been recognized as a "standardization work advanced unit" for two consecutive years by the National Medical Extracorporeal Circulation Equipment Standardization Technical Committee[120]. Future Outlook - The global medical device market is projected to grow from $405 billion in 2017 to $699 billion by 2025, with a CAGR of 7.0%[42]. - The company aims to enhance the quality of life for dialysis patients through continuous product development and innovation in the blood purification field[38]. - The company is committed to continuous innovation in infusion product materials and designs, focusing on safety and comfort for patients[68]. - The company is increasing its research and innovation efforts to address clinical treatment challenges faced by dialysis patients[166].

Financial Performance - The company's operating revenue for Q1 2023 was ¥272,919,002.98, a decrease of 15.11% compared to ¥321,497,637.25 in the same period last year[4] - The net profit attributable to shareholders was ¥44,785,584.88, down 5.61% from ¥47,447,455.87 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥36,384,675.79, a decline of 22.21% compared to ¥46,771,607.79 in the previous year[4] - The company reported a total profit of CNY 55,017,634.32 for Q1 2023, down 3.8% from CNY 57,334,356.70 in the same quarter last year[20] - Net profit for Q1 2023 was CNY 47,667,602.73, a decline of 5.4% from CNY 50,359,581.15 in Q1 2022[20] - Earnings per share for Q1 2023 were CNY 0.1127, compared to CNY 0.1204 in Q1 2022, reflecting a decrease of 5.7%[20] Cash Flow - The net cash flow from operating activities was -¥34,889,965.06, a significant decrease of 334.65% from ¥14,868,783.06 in the same period last year[4] - Cash inflow from investment activities totaled 25,221,763.58, down from 41,305,600.49, reflecting reduced investment returns[24] - The net cash flow from financing activities increased to 60,845,893.26, compared to 35,765,877.19 in the prior period, showing improved financing capabilities[24] - Cash received from sales of goods and services was 267,165,289.80, down from 332,918,108.44, reflecting a decline in revenue generation[23] - Cash paid for purchasing goods and services was 201,696,949.97, slightly decreased from 205,756,253.81, indicating stable cost management[23] - Cash inflow from other operating activities was 26,006,178.31, an increase from 17,596,721.84, suggesting improved operational efficiency[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,784,933,256.98, a slight decrease of 0.09% from ¥1,786,535,673.29 at the end of the previous year[4] - The equity attributable to shareholders increased by 4.44% to ¥1,123,946,838.23 from ¥1,076,120,829.73 at the end of the previous year[4] - The company's total liabilities as of Q1 2023 amounted to CNY 587,264,070.27, down from CNY 631,130,435.41 in the previous year[19] - Total current assets decreased from ¥689,282,923.80 at the beginning of the year to ¥662,626,342.45 at the end of the period, representing a decline of approximately 3.5%[15] - Total non-current assets increased from ¥1,097,252,749.49 to ¥1,122,306,914.53, showing an increase of approximately 2.3%[16] - Accounts payable decreased from ¥149,663,372.50 to ¥103,996,608.34, a reduction of about 30.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,596, with the largest shareholder holding 24.73% of the shares[10] Other Income and Expenses - Other income increased by 204.66% to ¥8,511,533.70, primarily due to an increase in government subsidies received[9] - Investment income rose significantly by 456.05% to ¥1,069,361.58, attributed to increased financial investment returns[9] - Research and development expenses for Q1 2023 were CNY 7,483,945.25, a decrease of 21.1% from CNY 9,481,656.95 in Q1 2022[19] Operational Insights - The company continues to focus on market expansion and new product development strategies to enhance future growth prospects[19] - The company’s first-quarter report was not audited, which may affect the reliability of the financial data presented[25]